Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries
Even for products centrally approved, each European country is responsible for national market access after European Medicines Agency (EMA) approval. This step can result in inequalities in terms of access, due to different opinions about the therapeutic value assessed by Health Technology Assessment (HTA) bodies. This study aims to provide a comparative analysis of HTA recommendations issued by EU countries (France, Germany, and Italy) for new neurological drugs following EMA approval. In the reference period, we identified 11 innovative medicines authorized in Europe for five neurological diseases (cerebral adrenoleukodystrophy, spinal muscular atrophy, metachromatic leukodystrophy, migraine, and polyneuropathy in patients with hereditary transthyretin amyloidosis), including eight drugs for genetic rare diseases. We found no agreement on the therapeutic value (in particular the “added value” compared to the standard of care) of the selected drugs. Despite the differences in terms of assessment, the access has been usually guaranteed even if with various types of limitations. The heterogeneity of the HTA assessment of clinical data among countries is probably related to the uncertainties about clinical value at the time of EMA approval and the lack of long-term data and of direct comparison with available alternatives. Given the importance of new medicines especially for rare diseases, it is crucial to understand and act on the causes of inconsistency among the HTA assessments, in order to ensure rapid and uniform access to innovation for patients who can benefit..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in Pharmacology - 12(2022) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lucia Gozzo [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Access |
|---|
| doi: |
10.3389/fphar.2021.823199 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ011682779 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ011682779 | ||
| 003 | DE-627 | ||
| 005 | 20230502073204.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2021.823199 |2 doi | |
| 035 | |a (DE-627)DOAJ011682779 | ||
| 035 | |a (DE-599)DOAJ08ee138a603449bfb9a590643ed6498b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Lucia Gozzo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Even for products centrally approved, each European country is responsible for national market access after European Medicines Agency (EMA) approval. This step can result in inequalities in terms of access, due to different opinions about the therapeutic value assessed by Health Technology Assessment (HTA) bodies. This study aims to provide a comparative analysis of HTA recommendations issued by EU countries (France, Germany, and Italy) for new neurological drugs following EMA approval. In the reference period, we identified 11 innovative medicines authorized in Europe for five neurological diseases (cerebral adrenoleukodystrophy, spinal muscular atrophy, metachromatic leukodystrophy, migraine, and polyneuropathy in patients with hereditary transthyretin amyloidosis), including eight drugs for genetic rare diseases. We found no agreement on the therapeutic value (in particular the “added value” compared to the standard of care) of the selected drugs. Despite the differences in terms of assessment, the access has been usually guaranteed even if with various types of limitations. The heterogeneity of the HTA assessment of clinical data among countries is probably related to the uncertainties about clinical value at the time of EMA approval and the lack of long-term data and of direct comparison with available alternatives. Given the importance of new medicines especially for rare diseases, it is crucial to understand and act on the causes of inconsistency among the HTA assessments, in order to ensure rapid and uniform access to innovation for patients who can benefit. | ||
| 650 | 4 | |a orphan drugs | |
| 650 | 4 | |a neurological diseases | |
| 650 | 4 | |a access | |
| 650 | 4 | |a added therapeutic benefit | |
| 650 | 4 | |a drug value | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Lucia Gozzo |e verfasserin |4 aut | |
| 700 | 0 | |a Giovanni Luca Romano |e verfasserin |4 aut | |
| 700 | 0 | |a Serena Brancati |e verfasserin |4 aut | |
| 700 | 0 | |a Marco Cicciù |e verfasserin |4 aut | |
| 700 | 0 | |a Luca Fiorillo |e verfasserin |4 aut | |
| 700 | 0 | |a Laura Longo |e verfasserin |4 aut | |
| 700 | 0 | |a Daniela Cristina Vitale |e verfasserin |4 aut | |
| 700 | 0 | |a Filippo Drago |e verfasserin |4 aut | |
| 700 | 0 | |a Filippo Drago |e verfasserin |4 aut | |
| 700 | 0 | |a Filippo Drago |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Pharmacology |d Frontiers Media S.A., 2010 |g 12(2022) |w (DE-627)DOAJ000099732 |x 16639812 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fphar.2021.823199 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/08ee138a603449bfb9a590643ed6498b |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fphar.2021.823199/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1663-9812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 | ||